At Ansun, we follow the data and not the crowd. Innovation is the engine that ignites our company and drives the pursuit of objectives. In everything we do, Ansun follows the same approach: first we understand the science. What is the prevailing science, and what are the gaps and the limitations? Why are there no treatments or why do current treatments fail? Who are the patients that respond to treatments and who are the patients left without useful options? We ask ourselves these questions every day, and we look for approaches that others reject. Ultimately, we challenge ourselves to think outside the box to address the unmet medical needs that threaten the most vulnerable among us!
That’s how we developed DAS181, a novel host-directed recombinant fusion protein that has the potential to treat not just every strain of the Flu virus, including every pandemic strain, but every strain of every virus that uses sialic acid to infect people.
How Does DAS181 Work:
Influenza viruses infect the human airway by binding to the lung surface and then getting inside the epithelial cells. The viruses do this by interacting with sialic acids that are part of sugars or lipids on the cell surface, and can internalize using a protein that also has a sialic acid. So sialic acid has a critical function in the ability of influenza to infect the human airway. DAS181 is a recombinant sialidase enzyme that works by removing sialic acids from the lung surface so that influenza cannot bind to infect. This interrupts the virus lifecycle and allows patients the chance to recover. By targeting the host rather than the virus, DAS181 is less susceptible to drug resistant strains of virus, and by targeting the host rather than a specific virus, DAS181 works for other viruses that use sialic acid receptors, such as parainfluenza virus, human metapneumovirus and enterovirus 68. DAS181 is currently being evaluated in a worldwide Phase 3 clinical trial in hospitalized patients infected with parainfluenza virus, and a Phase 2 trial in hospitalized patients with severe influenza infection is currently being planned.